Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics

T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives

(2020) Feiqi Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates

(2019) Haleh Saber et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatotoxicity with antibody maytansinoid conjugates: A review of preclinical and clinical findings

(2018) Sarah Taplin et al.   JOURNAL OF APPLIED TOXICOLOGY

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production

(2018) Gennaro Riccio et al.   Frontiers in Physiology

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Payload of T-DM1 binds to cell surface cytoskeleton-associated protein 5 to mediate cytotoxicity of hepatocytes

(2018) Yukinori Endo et al.   Oncotarget

Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia

(2017) Hui Zhao et al.   MOLECULAR CANCER THERAPEUTICS

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

(2016) John Y. Li et al.   CANCER CELL

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2016) Arlene Chan et al.   LANCET ONCOLOGY

Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes

(2016) Nishant Mohan et al.   MOLECULAR CANCER THERAPEUTICS

Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity

(2015) H. Yan et al.   MOLECULAR CANCER THERAPEUTICS

An FDA oncology analysis of antibody-drug conjugates

(2015) Haleh Saber et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)

(2014) H. Uppal et al.   CLINICAL CANCER RESEARCH

The necessity of and strategies for improving confidence in the accuracy of western blots

(2014) Rajeshwary Ghosh et al.   Expert Review of Proteomics

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

(2014) W. Dokter et al.   MOLECULAR CANCER THERAPEUTICS

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice

(2013) M. Khair ElZarrad et al.   PLoS One

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

(2013) Kirsten Achilles Poon et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Mechanisms of cardiotoxicity associated with ErbB2 inhibitors

(2012) Carmine Fedele et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

(2012) Sandhya Girish et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism

(2012) Ben-Quan Shen et al.   CURRENT DRUG METABOLISM

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors

(2011) Carmine Fedele et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer

(2011) Mark Barok et al.   CANCER LETTERS

The Cardioprotective Role of Probucol Against Anthracycline and Trastuzumab-Mediated Cardiotoxicity

(2011) Jonathan R. Walker et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents

(2009) Gennaro Riccio et al.   FASEB JOURNAL

Utility of Tissue Doppler and Strain Rate Imaging in the Early Detection of Trastuzumab and Anthracycline Mediated Cardiomyopathy

(2009) Davinder S. Jassal et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH